AI Article Synopsis

  • - Rheumatoid arthritis (RA) is linked to glycolysis, prompting this study to use 2-deoxy-D-glucose (2-DG), a glycolysis inhibitor, to treat rats with collagen-induced arthritis (CIA) and explore metabolic changes.
  • - 2-DG treatment significantly improved CIA symptoms and led to notable shifts in metabolic pathways related to bile secretion and cholesterol metabolism in the plasma, liver, and spleen, with gene expression changes primarily observed in the spleen.
  • - The study found specific metabolites that changed during CIA and after 2-DG treatment, indicating that both liver and spleen metabolism are affected by glycolysis in the progression of collagen-induced arthritis.

Article Abstract

Rheumatoid arthritis (RA) is significantly associated with glycolysis. This study used 2-deoxy-D-glucose (2-DG), an inhibitor of glycolysis, to treat rats with collagen-induced arthritis (CIA) and investigate the metabolic regulatory mechanism of glycolysis in the disease. 2-DG significantly alleviated CIA. Metabolomics and transcriptomics, as well as their integrative analysis, detected significant changes in the pathways of bile secretion, cholesterol and linoleic acid metabolism in the plasma, liver and spleen during the CIA process and the opposite changes following 2-DG treatment, whereas the expression of the genes regulating these metabolic pathways were changed only in the spleen. In the rat liver, levels of (S)-5-diphosphomevalonic acid in the terpenoid backbone biosynthesis pathway were significantly decreased during CIA progression and increased following 2-DG treatment, and levels of taurochenodeoxycholic acid in the pentose and glucuronate interconversions pathway showed the opposite results. In the spleen, levels of 3-methoxy-4-hydroxyphenylglycol glucuronide in bile secretion and 12(S)-leukotriene B4 in arachidonic acid metabolism were significantly decreased during CIA progression and increased following 2-DG treatment. The changes in the gene-metabolite network of bile secretion in the spleen correlated with a decreased plasma L-acetylcarnitine level in CIA rats and an increase following 2-DG treatment. Our analysis suggests the involvement of spleen and liver metabolism in CIA under the control of glycolysis.

Download full-text PDF

Source
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC8440946PMC
http://dx.doi.org/10.3389/fimmu.2021.713799DOI Listing

Publication Analysis

Top Keywords

2-dg treatment
16
bile secretion
12
collagen-induced arthritis
8
spleen liver
8
acid metabolism
8
decreased cia
8
cia progression
8
progression increased
8
increased 2-dg
8
cia
7

Similar Publications

Mesoporous polydopamine composite nanoparticles for multimodal therapy based on disrupting the redox homeostasis within tumor cells.

J Colloid Interface Sci

December 2024

Molecular Diagnostic Center, Key Laboratory of Clinical Cancer Pharmacology and Toxicology Research of Zhejiang Province, Hangzhou First People's Hospital, Hangzhou 310006, China. Electronic address:

Developing multimodal combination therapy strategies to disrupt the redox homeostasis within tumor cells is currently an important approach in cancer treatment. In this study, we designed and prepared multifunctional composite nanoparticles MPDA-PEG@MnO@2-DG (MPPMD NPs) utilizing mesoporous polydopamine nanoparticles (MPDA NPs) as carriers. These carriers were coated with polyethylene glycol (PEG), and manganese dioxide (MnO) and loaded with 2-deoxy-d-glucose (2-DG).

View Article and Find Full Text PDF

Texture analysis generates image parameters from F-18 fluorodeoxyglucose positron emission tomography/computed tomography (FDG PET/CT). Although some parameters correlate with tumor biology and clinical attributes, their types and implications can be complex. To overcome this limitation, pseudotime analysis was applied to texture parameters to estimate changes in individual sample characteristics, and the prognostic significance of the estimated pseudotime of primary tumors was evaluated.

View Article and Find Full Text PDF

Prognostic value of interim PET/CT in GCB and non-GCB DLBCL: comparison of the Deauville five-point scale and the ΔSUVmax method.

BMC Cancer

December 2024

Department of Nuclear Medicine, School of Medicine, Shanghai General Hospital, Shanghai JiaoTong University, Shanghai, 200080, China.

Background: This study aimed to identify the prognostic value of interim F-FDG PET/CT (I-PET) for germinal center B-cell-like (GCB) and non-GCB diffuse large B-cell lymphoma (DLBCL), respectively.

Methods: Baseline F-FDG PET/CT (B-PET) and I-PET scans were performed in 112 patients with DLBCL. The prognostic value of I-PET using the Deauville five-point scale (D-5PS) criteria or percentage decrease in SUVmax (∆SUVmax) for GCB and non-GCB DLBCL were evaluated.

View Article and Find Full Text PDF

Disease burden is a critical determinant of outcomes in CAR-T therapy for B-cell lymphomas, and one of the most widely used techniques for its assessment is Total Metabolic Tumor Volume (TMTV) measured via [F]FDG PET/CT. Biological parameters may further refine the risk profile. We analyzed baseline [F]FDG PET/CT scans from 40 patients treated with CAR-T, using an AI-based automated segmentation algorithm to determine TMTV.

View Article and Find Full Text PDF

Comparison of Plasma p-tau217 and [F]FDG-PET for Identifying Alzheimer Disease in People With Early-Onset or Atypical Dementia.

Neurology

January 2025

Translational Neuroimaging Laboratory, The McGill University Research Centre for Studies in Aging, McConnell Brain Imaging Centre, Montreal Neurological Institute, McGill University, Montreal, Quebec, Canada.

Background And Objectives: To compare the diagnostic performance of an immunoassay for plasma concentrations of phosphorylated tau (p-tau) 217 with visual assessments of fluorine-18 fluorodeoxyglucose [F]FDG-PET in individuals who meet appropriate use criteria for Alzheimer dementia (AD) biomarker assessments.

Methods: We performed a retrospective analysis of individuals with early-onset (age <65 years at onset) and/or atypical dementia (features other than memory at onset), who were evaluated at a tertiary care memory clinic. All participants underwent measurements of CSF biomarkers (Aβ42, p-tau181, and total tau levels), as well as [F]FDG-PET scans, amyloid-PET scans, and plasma p-tau217 quantifications.

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!